Preparation and characterization of a beta-lactamase-Fab' conjugate for the site-specific activation of oncolytic agents.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Bioconjugate chemistry

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/BC00013A007PMID 1616948
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Selective killing of carcinoembryonic-antigen (CEA)-producing cells in vitro by the immunoconjugate cytorhodin-S and CEA-reactive cytorhodin-S antibody CA208

  2005cited by this paper
• Effects of methotrexate-carcinoembryonic-antigen-antibody immunoconjugates on GW-39 human tumors in nude mice

  2005cited by this paper
• Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide

  2005cited by this paper
• Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids

  2004cited by this paper
• Drug localisation and growth inhibition studies of vindesine-monoclonal anti-CEA conjugates in a human tumour xenograft

  2004cited by this paper
• Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids

  2004cited by this paper
• A novel targeted delivery system utilizing a cephalosporin-oncolytic prodrug activated by an antibody β-lactamase conjugate for the treatment of cancer

  1991cited by this paper
• Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.

  1991cited by this paper
• Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2.

  1990cited by this paper
• Activation of prodrugs by antibody‐enzyme conjugates: a new approach to cancer therapy

  1990cited by this paper
• Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody.

  1990cited by this paper
• Expression and characterization of a chimeric bifunctional antibody with therapeutic applications.

  1990cited by this paper
• Structure-reactivity relationship for base-promoted hydrolysis and methanolysis of monocyclic .beta.-lactams

  1990cited by this paper
• Effect of the 3'-leaving group on turnover of cephem antibiotics by a class C beta-lactamase.

  1989cited by this paper
• Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates.

  1989cited by this paper
• Cloning and high level expression of a chimeric antibody with specificity for human carcinoembryonic antigen.

  1988cited by this paper
• A survey of the kinetic parameters of class C beta-lactamases. Cephalosporins and other beta-lactam compounds.

  1988cited by this paper
• Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate.

  1988cited by this paper
• Interactions of new plasmid-mediated beta-lactamases with third-generation cephalosporins.

  1988cited by this paper
• Sequence and comparative analysis of three Enterobacter cloacae ampC beta-lactamase genes and their products.

  1988cited by this paper
• Tumour therapy with vinca alkaloids targeted by a hybrid‐hybrid monoclonal antibody recognising both CEA and vinca alkaloids

  1988cited by this paper
• A cytotoxic agent can be generated selectively at cancer sites.

  1988cited by this paper
• Common mechanism of ampC beta-lactamase induction in enterobacteria: regulation of the cloned Enterobacter cloacae P99 beta-lactamase gene

  1987cited by this paper
• Cryoenzymology of beta-lactamases.

  1987cited by this paper
• Direct observation by proton NMR of cephalosporoate intermediates in aqueous solution during the hydrazinolysis and .beta.-lactamase-catalyzed hydrolysis of cephalosporins with 3' leaving groups: kinetics and equilibria of the 3' elimination reaction

  1986cited by this paper
• Interactions of cephalosporins with the Streptomyces R61 DD-transpeptidase/carboxypeptidase. Influence of the 3'-substituent.

  1986cited by this paper
• Conscripting β-Lactamase for Use in Drug Delivery. Synthesis and Biological Activity of a Cephalosporin C10-Ester of an Antibiotic Dipeptide.

  1986cited by this paper
• Leaving group ability and pKa in elimination reactions

  1985cited by this paper
• Elucidating the leaving group effect in the β-lactam ring opening mechanism of cephalosporins

  1985cited by this paper
• Purification of beta-lactamases by affinity chromatography on phenylboronic acid-agarose.

  1984cited by this paper
• Mechanism of .beta.-lactam ring opening in cephalosporins

  1984cited by this paper
• Electronic structures of cephalosporins and penicillins. 15. Inductive effect of the 3-position side chain in cephalosporins.

  1984cited by this paper
• Chemotherapy with daunorubicin-anti-CEA conjugates in human colon adenocarcinoma grafted in nude mice.

  1984cited by this paper
• A chlorambucil-anti-CEA conjugate cytotoxic for human colon adenocarcinoma cells in vitro.

  1984cited by this paper
• Elimination of a good leaving group from the 3'-position of a cephalosporin need not be concerted with .beta.-lactam ring opening: TEM-2 .beta.-lactamase-catalyzed hydrolysis of pyridine-2-azo-4'-(N',N'-dimethylaniline) cephalosporin (PADAC) and of cephaloridine

  1984cited by this paper
• Crystallographic data for the beta-lactamase from Enterobacter cloacae P99.

  1983cited by this paper
• Relative substrate affinity index values: a method for identification of beta-lactamase enzymes and prediction of successful beta-lactam therapy

  1983cited by this paper
• Crystallographic data for the β-lactamase from Enterobacter cloacae P99

  1983cited by this paper
• Resistance to cefamandole: derepression of beta-lactamases by cefoxitin and mutation in Enterobacter cloacae.

  1982cited by this paper
• In vitro evaluation of CENTA, a new beta-lactamase-susceptible chromogenic cephalosporin reagent

  1982cited by this paper
• Electronic structures of cephalosporins and penicillins. 9. Departure of a leaving group in cephalosporins.

  1979cited by this paper
• Conjugation of glucose oxidase from Aspergillus niger and rabbit antibodies using N-hydroxysuccinimide ester of N-(4-carboxycyclohexylmethyl)-maleimide.

  1979cited by this paper
• Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.

  1979cited by this paper
• Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.

  1978cited by this paper
• Electronic structures of cephalosporins and penicillins. 4. Modeling acylation by the beta-lactam ring.

  1975cited by this paper
• Novel Method for Detection of β-Lactamases by Using a Chromogenic Cephalosporin Substrate

  1972cited by this paper
• Observations on the nature, distribution, and significance of cephalosporinase.

  1963cited by this paper

• β-Lactamase-Mediated Fragmentation: Historical Perspectives and Recent Advances in Diagnostics, Imaging, and Antibacterial Design.

  2022cites this paper
• Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and Nonreplicating Mycobacterium tuberculosis.

  2019cites this paper
• Engineering of Escherichia coli β-lactamase TEM-1 variants showing higher activity under acidic conditions than at the neutral pH.

  2018cites this paper
• Enzymatic functionalization of a nanobody using protein insertion technology.

  2015cites this paper
• How to make good use of a “bad” enzyme: utilization of efficient β-lactamases for the benefits of biochemical research

  2012cites this paper
• Anti-angiogenic peptides for cancer therapeutics.

  2011cites this paper
• Anticancer prodrugs: an overview of major strategies and recent developments.

  2011cites this paper
• The osteogenic effect of bone morphogenetic protein-2 on the collagen scaffold conjugated with antibodies.

  2010cites this paper
• Functional copolymers of N-isopropylacrylamide for bioengineering applications

  2007cites this paper
• jY-(4'-Hydroxyphenylacetyl)palytoxin: A Palytoxin Prodrug That Can Be Activated by a Monoclonal Antibody-Penicillin G Amidase Conjugate1

  2006cites this paper
• Antibody conjugates and therapeutic strategies.

  2005cites this paper
• Tumor-activated Prodrugs—A New Approach to Cancer Therapy

  2004cites this paper
• Enzyme/abzyme prodrug activation systems: potential use in clinical oncology.

  2003cites this paper
• Prodrug strategies in cancer therapy.

  2001cites this paper
• Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs.

  1999cites this paper
• The Design and Synthesis of Prodrugs for Antibody-Directed Enzyme Prodrug Therapy (ADEPT)

  1999cites this paper
• Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations.

  1999cites this paper
• Enzymes and Prodrugs Used for ADEPT

  1999cites this paper
• The Design of Selectively‐activated Anti‐cancer Prodrugs for use in Antibody‐directed and Gene‐directed Enzyme‐Prodrug Therapies *

  1998cites this paper
• Concept, design, and preclinical evaluation of quinolonyl lactam antibacterials.

  1998cites this paper
• The development of beta-lactamase as a highly versatile genetic reporter for eukaryotic cells.

  1997cites this paper
• Antibody-directed enzyme prodrug therapy (ADEPT): a review.

  1997cites this paper
• Dextran modification of a Fab'--beta-lactamase conjugate modulated by variable pretreatment of Fab' with amine-blocking reagents.

  1996cites this paper
• Preparation and Purification of Antibody-Enzyme Conjugates for Therapeutic Applications

  1996cites this paper
• A summary of monoclonal antibody-enzyme/prodrug

  1996cites this paper
• Section Review: Biologicals & Immunologicals: Development of prodrugs for ADEPT (antibody-directed enzyme prodrug therapy)

  1996cites this paper
• Prodrugs of anticancer agents

  1996cites this paper
• Antibody-enzyme conjugates for cancer therapy.

  1996cites this paper
• Advanced drug delivery reviews : enzyme prodrug therapy

  1996cites this paper
• The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.

  1995cites this paper
• Antibody-Directed Enzyme Prodrug Therapy

  1995cites this paper
• Site-specific prodrug activation by antibody-beta-lactamase conjugates: preclinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody directed catalysis.

  1995cites this paper
• Prodrugs in cancer chemotherapy

  1995cites this paper
• Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.

  1995cites this paper
• In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.

  1995cites this paper
• Antibody-directed enzyme prodrug therapy.

  1995cites this paper
• Increased protein expression through improved ribosome-binding sites obtained by library mutagenesis.

  1994cites this paper
• High yield, site-specific coupling of N-terminally modified beta-lactamase to a proteolytically derived single-sulfhydryl murine Fab'.

  1994cites this paper
• Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates.

  1994cites this paper
• Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates.

  1994cites this paper
• Targeting enzymes for cancer therapy: old enzymes in new roles.

  1994cites this paper
• A bifunctional murine::human chimeric antibody with one antigen-binding arm replaced by bacterial beta-lactamase.

  1994cites this paper
• Synthesis and characterization of monoclonal antibody-beta-lactamase conjugates.

  1994cites this paper
• Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models.

  1993cites this paper
• Generation of cytotoxic agents by targeted enzymes.

  1993cites this paper
• Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-beta-lactamase conjugates.

  1993cites this paper
• Recombinant human monoclonal antibodies

  1992cites this paper
• Monoclonal antibody-beta-lactamase conjugates for the activation of a cephalosporin mustard prodrug.

  1992cites this paper
• Recombinant human monoclonal antibodies. Basic principles of the immune system transferred to E. coli.

  1992cites this paper
• N-(4'-hydroxyphenylacetyl)palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate.

  1992cites this paper